P27 in cell cycle control and cancer

Leukemia and Lymphoma

Volumn 39, Issue 1-2, 2000, Pages 19-27

  Moller, M B ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Cancer; Cell cycle; Cyclin dependent kinase inhibitor; Lymphoma; P27; Prognosis

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P27;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER; CANCER CELL; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REGULATION; GENE MUTATION; KNOCKOUT MOUSE; LYMPHOMA; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PHASE TRANSITION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW;

EID: 0033842355     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190009053535     Document Type: Review

References (111)

1. Checkpoints: Controls that ensure the order of cell cycle events
2. Cyclins, CDKs and cancer
3. Cyclins and cancer II: Cyclin D and CDK inhibitors come of age
4. Unrestricted cell cycling and cancer
5. Cell cycle control and cancer
6. Cancer cell cycles
7. Inhibitors of mammalian G1 cyclin-dependent kinases
8. A restriction point for control of normal animal cell proliferation
9. G1 events and regulation of cell proliferation
10. The retinoblastoma protein and cell cycle control
11. Cell cycle and cancer
12. p21 is a universal inhibitor of cyclin kinases
13. Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes
14. p21-containing cyclin kinases exist in both active and inactive states
15. WAF1, a potential mediator of p53 tumor suppression
16. Inhibition of CDK2 activity in vivo by an associated 20K regulatory sub-unit
17. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases
18. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen
19. Inhibition of cyclin-dependent kinases by p21
20. Inhibition of oncogene-mediated transformation by ectopic expression of p21(Waf1) in NIH3T3 cells
21. p21 disrupts the interaction between cdk2 and the E2F-p130 complex
22. Inhibition of E2F activity by the cyclin-dependent protein kinase inhibitor p21 in cells expressing or lacking a functional retinoblastoma protein
23. A role for a p21-E2F interaction during senescence arrest of normal human fibroblasts
24. Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation
25. 1 arrest and long-term induction of Cip1 in normal human fibroblasts
26. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest
27. Radiation-induced cell cycle arrest compromised by p21 deficiency
28. 1 arrest in human cancer cells
29. Cyclin D1 and p21/waf1 are both involved in p53 growth suppression
30. Requirement for tyrosine phosphorylation of Cdk4 in G1 arrest induced by ultraviolet irradiation
31. Cyclin-dependent kinases are inactivated by a combination of p21 and Thr-14/Tyr-15 phosphorylation after UV-induced DNA damage
32. Role for c-Abl tyrosine kinase in growth arrest response to DNA damage
33. Uncoupling of S phase and mitosis induced by anti-cancer agents in cells lacking p21
34. Mice lacking p21(CIP/WAF1) undergo normal development, but are defective in G1 checkpoint control
35. Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis
36. Genetic determinants of p53-induced apoptosis and growth arrest
37. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
38. Tumor spectrum analysis in p53-mutant mice
39. Cooperative tumorigenic effects of germline mutations in Rb and p53
40. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice
41. Induction of WAF1/CIP1 by a p53-independent pathway
42. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage
43. Induction of p21 (WAF-1/CIP1) during differentiation
44. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53
45. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD
46. Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinase
47. p53-independent expression of p21(Cip1) in muscle and other terminally differentiating cells
48. 3 leads to the induced differentiation of the myelomonocytic cell line U937
49. Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins
50. Assignment of the human p27(Kip1) gene to 12p13 and its analysis in leukemias
51. Cloning of p27(Kip1), a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals
52. A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor β-arrested epithelial cells
53. A cell cycle-related inhibitor of cyclin-dependent kinases
54. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21
55. Requirement of p27(Kip1) for restriction point control of the fibroblast cell cycle
56. p27(Kip1), a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest
57. TGFβ inhibition of cdk4 synthesis is linked to cell cycle arrest
58. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27(Kip1)) of cyclin-dependent kinase 4 activation
59. Interleukin-2-mediated elimination of the p27(Kip1) cyclin-dependent kinase inhibitor prevented by rapamycin
60. 0 state) in fibroblasts
61. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1)
62. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice
63. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27
64. A commentary on the 1996 American Association for Cancer Research Meeting - ″Cancer susceptibility genes and molecular carcinogenesis″
65. Cloning of p57(KIP2), a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution
66. p57(KIP2), a structurally distinct member of the p21(CIP1) Cdk inhibitor family, is a candidate tumor suppressor gene
67. New functional activities for the p21 family of cdk inhibitors
68. The p21(Cip1) and p27(Kip1) CDK ″inhibitors″ are essential activators of cyclin D-dependent kinases in murine fibroblasts
69. Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor p27(Kip1) with cyclin A-Cdk2 and cyclin D2-Cdk4
70. 1-phase progression
71. Regulation of the cyclin E gene by transcription factor E2F1
72. Regulation of cyclin E transcription by E2Fs and retinoblastoma protein
73. Cyclin E-CDK2 is a regulator of p27(Kip1)
74. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27(Kip1)
75. The murine gene p27(Kip1) is haplo-insufficient for tumour suppression
76. p27(Kip1): Chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors
77. p27/Kip1 mutation found in breast cancer
78. Frequent loss of heterozygosity in region of the KIP1 locus in non-small cell lung cancer: Evidence for a new tumor suppressor gene on the short arm of chromosome 12
79. Mutational analysis of the candidate tumor suppressor genes TEL and KIP1 in childhood acute lymphoblastic leukemia
80. Molecular analysis of cyclin-dependent kinase inhibitors in human leukemias
81. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas
82. Decreased levels of the cell-cycle inhibitor p27(Kip1) protein: Prognostic implications in primary breast cancer
83. Expression of cell-cycle regulators p27(Kip1) and cyclin E, alone and in combination, correlate with survival in young breast cancer patients
84. Prognostic role of p27(Kip1) and apoptosis in human breast cancer
85. Loss of cyclin-dependent kinase inhibitor p27(Kip1) is a novel prognostic factor in localized human prostate adenocarcinoma
86. Association of p27(Kip1) levels with recurrence and survival in patients with stage C prostate carcinoma
87. Distinct altered patterns of p27(KIP1) gene expression in benign prostatic hyperplasia and prostatic carcinoma
88. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma
89. Positive correlation between p27(Kip1) expression and progression of human esophageal squamous cell carcinoma
90. p27 expression and gastric carcinoma
91. Expression of the cell cycle inhibitor p27(KIP1) is a new prognostic marker associated with survival in epithelial ovarian tumors
92. Reduced expression of the cell cycle inhibitor p27(Kip1) in non-small cell lung carcinoma: A prognostic factor independent of ras
93. Loss of p27(Kip1) expression independently predicts poor prognosis for patients with resectable pancreatic adenocarcinoma
94. Protein expression of the cell-cycle inhibitor p27(Kip1) in malignant melanoma: Inverse correlation with disease-free survival
95. Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas: Prognostic implications
96. Clinical significance of cyclin-dependent kinase inhibitor p27(Kip1) expression and proliferation in non-Hodgkin's lymphoma: Independent prognostic value of p27(Kip1)
97. p27(KIP1) is abnormally expressed in diffuse large B-cell lymphomas and is associated with an adverse clinical outcome
98. Absence of WAF1 mutations in a variety of human malignancies
99. A mutant p21 cyclin-dependent kinase inhibitor isolated from a Burkitt's lymphoma
100. 94 → Trp) identified in a human breast carcinoma - Evidence that the mutation impairs the ability of p21 to inhibit cyclin-dependent kinases
101. Mutations and defective expression of the WAF1 p21 tumour-suppressor gene in malignant melanomas
102. Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, p27(Kip1), to regions involved in human cancer
103. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies
104. An imprinted gene p57(KIP2) is mutated in Beckwith-Wiedemann syndrome
105. Low frequency of p57(KIP2) mutation in Beckwith-Wiedemann-syndrome
106. New p57(KIP2) mutations in Beckwith-Wiedemann syndrome
107. Cyclin-dependent kinase inhibitor p27(KIP1) in lymphoid tissue. p27(KIP1) expression is inversely proportional to the proliferative index
108. Mantle cell lymphomas lack expression of p27(kip1), a cyclin-dependent kinase inhibitor
109. Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression. p27/KIP1-cyclin D3 colocalization in tumor cells
110. Loss of detectable p27 protein expression in mantle cell lymphomas (MCL) is a result of its sequestration by cyclin D1: Implications for pathogenesis
111. Prognostic significance of the cell cycle inhibitor p27(Kip1) in chronic B-cell lymphocytic leukemia